Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434817 | 0.89 | MTNR1A (0.40) | POLBMAPK1SMN1; SMN2ALDH1A1MTNR1A | |
| SCHEMBL6437950 | 0.88 | PTGDR2 (0.40) | POLBPTGDR2ALDH1A1ALOX15PTGDR | |
| SCHEMBL6435769 | 0.87 | PARP15 (0.38) | POLBPTGDR2SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL6434910 | 0.82 | CNR2 (0.33) | PTGDR2SMN1; SMN2PTGDR | |
| SCHEMBL6434913 | 0.82 | CNR2 (0.33) | PTGDR2SMN1; SMN2PTGDR | |
| SCHEMBL6434919 | 0.82 | CNR2 (0.33) | PTGDR2SMN1; SMN2PTGDR | |
| SCHEMBL6437898 | 0.80 | MTNR1A (0.41) | PTGDR2SMN1; SMN2ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL6437915 | 0.78 | PARP15 (0.36) | PTGDR2PTGDR | |
| SCHEMBL6434678 | 0.78 | ADORA2A (0.35) | PTGDR2MAPK1ALDH1A1ALOX15 | |
| SCHEMBL6433478 | 0.76 | GLA (0.35) | PTGDR2ALDH1A1HPGDMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | POLB 2696/4885PTGDR2 3263/4885MAPK1 4085/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | POLB 2696/4885PTGDR2 3263/4885MAPK1 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.